Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include interim phase 1b data for VERVE-102, the US Food and Drug Administration approval of linaclotide (Linzess) for pediatric patients ≥ 2 years of age with functional constipation (FC), the Priority Review of Zydus Therapeutics’ new drug application (NDA) for saroglitazar in adults with 

, new phase 3 data for bepirovirsen in adults with 

, and the FDA approval of insulin human (Afrezza) Inhalation Powder for use in children and adolescents aged 6 and older living with 

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of May 24, 2026 — let's jump in!

VERVE-102 Lowers PCSK9, LDL-C in Interim Phase 1b Hypercholesterolemia Data

On May 25, 2026, Eli Lilly reported interim phase 1b data for VERVE-102, an investigational 

 base-editing therapy targeting PCSK9, with dose-dependent reductions in circulating PCSK9 and 

low-density lipoprotein cholesterol (LDL-C)

 after a single intravenous infusion. The results were presented as a late-breaking oral presentation at the European Atherosclerosis Society Congress (EASC). The FDA has also granted Fast Track designation for VERVE-102 for LDL-C reduction in participants with hyperlipidemia and high lifetime cardiovascular risk.

FDA Approves Linaclotide (Linzess) for Functional Constipation in Patients 2 Years And Older

On May 27, 2026, the FDA approved Ironwood Pharmaceuticals’ linaclotide (Linzess) for pediatric patients ≥ 2 years of age with FC, expanding its previous approval for patients ≥ 6 years of age with FC. With this decision, linaclotide is now available for children ages 2-5 years with FC and remains the only FDA-approved prescription therapy for pediatric FC.

FDA Grants Priority Review to Saroglitazar NDA for Primary Biliary Cholangitis

On May 28, 2026, the FDA granted Priority Review to Zydus Therapeutics’ new drug application (NDA) for saroglitazar in adults with PBC. The application seeks approval for use with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in those unable to tolerate UDCA. The FDA has also assigned a Prescription Drug User Fee Act target action date of November 27, 2026. Zydus said it plans a US launch by March 2027 if the agent is approved.

Bepirovirsen Achieves 19% Functional Cure in Chronic Hepatitis B

On May 28, 2026, GSK announced pivotal phase 3 data for bepirovirsen, an investigational antisense oligonucleotide, showing a statistically significant functional cure rate of 19% in adults with chronic hepatitis B (CHB). Results were simultaneously published in the New England Journal of Medicine and presented at the European Association for the Study of the Liver (EASL) congress on May 28, 2026.

FDA Approves Inhaled Insulin Afrezza for Pediatric Patients With Diabetes

On May 29, 2026, the FDA approved insulin human (Afrezza) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes. It is the only ultra rapid-acting inhaled insulin approved by the FDA to improve glycemic control in children, adolescent, and adult patients with diabetes mellitus. The decision was based on results from the pivotal INHALE‑1 clinical trial, along with additional safety, efficacy, and long‑term exposure data from studies evaluating inhaled insulin over the past 2 decades of development.

Articles

Five near-term clinical and regulatory inflection points emerged across cardiometabolic, GI, hepatology, and endocrine care. A single-infusion in vivo base-editing candidate (VERVE‑102) produced dose-dependent PCSK9 and LDL‑C reductions, supported by FDA Fast Track. Linaclotide gained FDA approval for functional constipation down to age 2, remaining the only prescription option for pediatric FC. Saroglitazar received FDA Priority Review for primary biliary cholangitis with a November 2026 action date. Bepirovirsen delivered a 19% functional cure in phase 3 chronic hepatitis B. Afrezza was approved for pediatric diabetes ages 6+.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Hepatology

The HCPFive: Top News for Healthcare Providers from the Week of 05/24

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Retatrutide Provides Substantial Weight Loss in Patients With Obesity or Overweight

On May 21, 2026, Eli Lilly announced topline results from TRIUMPH-1, its phase 3 trial of retatrutide in adult patients with obesity or overweight with ≥1 weight-related comorbidity and without diabetes. At the 80 week endpoint of the trial, all doses of the GLP-1/GIP/glucagon triple agonist, including 4 mg, 9 mg, and 12 mg, saw major reductions in weight, with an average of 70.3 pounds lost across all 3 arms.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the implications of these significant data and speculate on the future of this promising new treatment for obesity.

Check out the full episode on the latest diabetes news

In this segment, Isaacs and Bellini frame the results as a major development in the rapidly evolving obesity treatment landscape, particularly as clinicians begin to move beyond single- and dual-incretin therapies toward more advanced multi-receptor approaches. Retatrutide is presented as a potential next-generation therapy capable of producing weight loss outcomes approaching those historically seen only with bariatric surgery.

The discussion emphasizes the study population and trial design, noting that participants did not have diabetes, an important distinction given that incretin-based therapies typically produce less weight reduction in patients with type 2 diabetes. Participants enrolled in the study had obesity or overweight accompanied by at least 1 obesity-related comorbidity, such as hypertension or hyperlipidemia. Isaacs and Bellini underscore the long-term nature of the trial, with primary endpoint analysis conducted at 80 weeks and extension data extending through 104 weeks, highlighting the importance of sustained treatment approaches for obesity as a chronic disease.

The speakers review the topline efficacy data across all 3 studied doses—4 mg, 9 mg, and 12 mg—stating that each dose met both primary and key secondary endpoints. Investigators reported average weight loss reaching 70.3 pounds, corresponding to a 28.3% reduction in body weight. Nearly half of participants, 45.3%, achieved at least 30% weight loss, results that the cohosts repeatedly compare to bariatric surgery outcomes. The extension-phase findings generated additional enthusiasm, particularly among participants with baseline BMI ≥35 kg/m², where average weight loss reportedly reached 85 pounds, or 30.3% of body weight, at 104 weeks. The speakers note that weight loss had not yet plateaued at the time of analysis, suggesting the possibility of additional reductions with longer follow-up.

Considerable attention is also given to tolerability and treatment adherence. The speakers highlight the unexpectedly favorable discontinuation data in the 4 mg arm, where discontinuation rates were reportedly lower than placebo. They characterize this as especially meaningful given the gastrointestinal adverse effects and adherence challenges commonly associated with GLP-1–based therapies. The simplified dosing structure, consisting of only 3 doses, is also described as a practical advantage for future clinical implementation.

The conversation then shifts toward the broader clinical implications of triple agonist therapies. Isaacs and Bellini outline upcoming studies within the broader TRIUMPH program, including trials evaluating retatrutide in obesity with type 2 diabetes and obesity with established cardiovascular disease. The speakers stress the importance of determining whether the profound weight reductions observed with triple agonism will also translate into cardiovascular risk reduction similar to that demonstrated with existing GLP-1 receptor agonists and dual agonists.

Finally, the cohosts reflects on the growing enthusiasm among patients, many of whom are already aware of the topline data through widespread media coverage. The speakers note increasing patient interest in pharmacologic alternatives to bariatric surgery, particularly among individuals seeking less invasive treatment options or those unable to accommodate surgical recovery. They conclude that retatrutide and other emerging triple agonists may represent the beginning of a new era in obesity medicine and chronic weight management, with anticipation building ahead of the full data presentation and potential publication expected at the upcoming ADA Scientific Sessions.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Eli Lilly. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. May 21, 2026. Accessed May 29, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss

Podcasts

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover topline data from the TRIUMPH-1 trial of retatrutide for obesity management.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Videos

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Jonathan A. Bernstein, MD: University of Cincinnati

) is increasingly recognized as a heterogeneous disease, with growing evidence supporting distinct endotypes characterized by different immunologic mechanisms and treatment responses. Investigators have focused on identifying biomarkers that may help distinguish between type I autoallergic and type IIb autoimmune CSU, particularly as newer targeted therapies expand treatment options.

Although several biomarkers, including total serum immunoglobulin E (IgE), thyroid peroxidase (TPO) antibodies, and functional basophil assays, have been associated with treatment outcomes, questions remain about their role in routine clinical practice. Much of the available evidence is derived from observational studies and post hoc analyses, and standardized approaches to biomarker-guided care have yet to be established.

At the 2026 Eastern Allergy Conference in Palm Beach, Florida, Jonathan Bernstein, MD, professor of medicine at the University of Cincinnati and a physician with Bernstein Allergy Group and the Bernstein Clinical Research Center, presented the session, “CSU Biomarkers and Advanced Treatments.” In an interview with HCPLive, Bernstein discussed the current landscape of CSU biomarkers, their potential clinical utility, and what additional evidence is needed to support biomarker-driven treatment selection.

 The field has increasingly described two major CSU endotypes—type I autoallergic and type IIb autoimmune—with distinct biomarker profiles and treatment responses. In your clinical practice, how reliably can you actually distinguish these endotypes using currently available tests, and do you think most community allergists have the tools and workflow to do this?

The question about biomarkers came about because of response or poor response to antihistamines and also to omalizumab, and so people started looking at biomarkers and looking at characteristics to see what would predict response or nonresponse.

Part of this depends on [whether] you are looking at individual biomarkers or a compilation, a composite number of biomarkers, and where you cut, what levels you cut, [and] what cut point you use, for instance, for IgE. What is your cut point? Is it 40 international units? Is it 100? Is it lower than 10 or 20?

When you start looking at really low levels, they're more predictive for response or nonresponse to omalizumab. When you start putting IgE together with thyroid peroxidase antibody and even CU indexes, which measure expression of certain receptors on basophils, they become more predictive. But most allergists are not using these biomarkers routinely in their analysis.

When we [started] looking at the newer agents like dupilumab and remibrutinib, which have been approved, there's less information about the utility. It appears thus far that dupilumab works regardless [of] whether an IgE level is high or low, although the cut point has been not very low. It’s like 100. I wouldn't call that anything below that low.

And then remibrutinib, we know that it works in patients who have autoimmune urticaria, and so it seems to respond to patients who aren't responders to omalizumab. So the verdict is still out.

I still feel that it's useful to order biomarkers because it's a conversation that can help patients understand where they are in terms of the types of urticaria they have and what they can expect in terms of treatment outcomes. I think there is a utility, but what we found out from omalizumab doesn't necessarily translate to dupilumab and to remibrutinib.

And [for] the newer agents, we have very little information about biomarkers. I know companies who are developing these therapies are checking biomarkers as exploratory assessments, but we don't have that information yet.

I think it is helpful and useful to order a few of these biomarkers. I limit it to total IgE and thyroid peroxidase antibody, and then I also get something called a CU Index, but that latter test is not validated yet, and it's not standardized adequately.

There's also the basophil activation test, which is another surrogate marker for autoimmune urticaria. It really depends on the individual patient.

 Biomarkers like total serum IgE, anti-thyroid antibodies, basophil counts, and functional assays have emerged as tools for differentiating between CSU subtypes. Which of these do you consider actionable today?

Very low IgEs, less than 20, are significant, and thyroid peroxidase antibodies are also very important. As I said, the CU Index is still [uncertain]. Some of the studies don't really show that by itself it's very predictive.

When you put these together, though, there is some value. We did a study that we published a few years ago, which showed that TPO was probably the most predictive, but when you looked at TPO in conjunction with IgE and CU index, that composite score was more predictive of poor response to omalizumab.

 Connections between identified biomarkers, genetic risk loci (lo-sigh), phenotypes, and their corresponding endotypes remain insufficiently characterized, with much of the available data coming from real-world or small-scale studies. What would it take to actually move biomarker-driven treatment selection into routine care?

 Well, it's going to take more real-world evidence to support these findings. Not everybody responds to these medications. Why do some people respond and others don't? It comes down to looking at responders and non-responders, their clinical characteristics, and then trying to identify other biomarkers.

It is important to characterize patients phenotypically because it's not one size fits all. The algorithm [does] not just start this and go to that. There [are]…some discussions that need to be had with patients.

Most of this is going to be longitudinal, real-world studies looking at responders and non-responders and trying to identify phenotypic and maybe genetic markers down the line. That's going to be a little bit more challenging, I think.

Bernstein discussed the evolving role of biomarkers in chronic spontaneous urticaria  at EAC 2026.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Endotyping & Biomarkers in CSU, With Jonathan Bernstein, MD

Discussing Zumilokibart Data in Atopic Dermatitis, With Ruth Ann Vleugels, MD, MPH, MBA

team, Ruth Ann Vleugels, MD, MPH, MBA, spoke about her team’s newly released 

 assessing the use of investigational IL-13 inhibitor zumilokibart (APG777) in adults with moderate-to-severe 

, noting what she described as notably strong efficacy results paired with a familiar and reassuring safety profile.

In her discussion, Vleugels said the data stood out not only because the study attained its primary endpoint of EASI-75 at the 16-week mark, but because several higher-threshold efficacy measures exceeded investigators’ expectations. She pointed specifically to the rates of EASI-90 and Investigator’s Global Assessment (IGA) 0/1 responses, noting that the numerical improvements appeared meaningfully higher than those seen historically with currently available biologic agents for atopic dermatitis. Vleugels also emphasized that earlier findings with the therapy suggest responses may continue to deepen beyond the initial 16-week induction period.

“[We] know from previous data that even past the initial 16 weeks there's additional improvement on this therapy, so the efficacy data is quite robust and exciting to those of us who take care of patients with atopic dermatitis,” she explained.

One of the most clinically meaningful findings, according to Vleugels, was the proportion of patients achieving very low disease activity (vLDA), a composite endpoint incorporating both skin clearance and itch control. Vleugels noted many individuals classified as treatment successes under traditional endpoints still experience residual symptoms, particularly pruritus, underscoring why clinicians increasingly view more stringent disease-control targets as needed.

Vleugels contrasted these outcomes with the efficacy profile of JAK inhibitors, which she acknowledged can achieve similarly high-level responses but may create hesitation among some clinicians because of boxed safety warnings involving cardiovascular events, malignancy, and thrombosis risk. In that context, she said a biologic capable of reaching comparable efficacy benchmarks could represent an important advancement for clinicians seeking highly effective options with a more established safety profile.

Regarding tolerability, Vleugels noted that the adverse event (AE) profile observed with zumilokibart aligned with prior experience using IL-4 and IL-13 pathway inhibitors. She characterized conjunctivitis, the most discussed adverse event in this therapeutic class, as generally manageable, often mild, and rarely severe enough to require discontinuation.

She also highlighted the therapy’s reduced injection frequency as a potentially important differentiator. According to Vleugels, maintenance dosing as infrequently as 2 to 4 times annually could substantially lessen treatment burden compared with currently available biologics, something she said patients consistently value in clinical practice.

Disclosures: Vleugels has previously reported serving as a principal investigator and/or consultant for Pfizer, AstraZeneca, Apogee, Priovant, BMS, Lilly, and Johnson & Johnson.

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis. Apogee Therapeutics. May 27, 2026. 

https://investors.apogeetherapeutics.com/news-releases/news-release-details/apogee-therapeutics-announces-positive-16-week-part-b-induction

Smith T. APEX: Positive 16-Week Data Released on Zumilokibart for Atopic Dermatitis. HCPLive. May 27, 2026. Accessed May 29, 2026. 

https://www.hcplive.com/view/apex-positive-16-week-data-released-zumilokibart-atopic-dermatitis

This interview highlights topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Tatiana V. Kudryashova, PhD, from the University of Pittsburgh.

2026 American Thoracic Society (ATS) International Conference 

in Orlando, Florida, investigators presented findings evaluating the role of E2F transcription factor 2 (E2F2) in pulmonary arterial smooth muscle cell (PASMC) proliferation in 

. The study focused on identifying signaling pathways downstream of homeodomain-interacting protein kinase-2 (HIPK2), a transcriptional coregulator previously associated with pro-proliferative and pro-survival signaling in PAH PASMCs.

Using RNA sequencing analysis of PAH PASMCs treated with the HIPK2 inhibitor tBID, investigators identified downregulation of several transcription factors, including MYBL2 and E2F2, with only E2F2 also demonstrating reduced protein expression on immunoblot analysis. Additional analyses using publicly available datasets and primary PASMC samples from patients with PAH showed increased E2F2 expression at both the mRNA and protein levels compared with non-diseased controls. Investigators also identified increased expression of TFDP1, a known binding partner of E2F2 involved in cell-cycle progression and growth-related gene activation.

The investigators further evaluated potential mechanisms regulating E2F2 expression and reported that E2F2 upregulation appeared independent of AKT kinase and YAP signaling pathways in siRNA- and inhibitor-based studies. Functional analyses demonstrated that siRNA-mediated downregulation of E2F2 significantly reduced proliferation in hyperproliferative PAH PASMCs as measured by BrdU incorporation. In this Q&A, Tatiana V. Kudryashova, PhD, from the University of Pittsburgh, discussed the study findings, the significance of E2F2 signaling in PAH, and future directions for evaluating anti-remodeling therapeutic approaches targeting proliferative pathways in the disease.

 Your work identifies E2F2 as upregulated in PAH smooth muscle cells. How central do you think this pathway is to the broader proliferative phenotype seen in pulmonary arterial hypertension?

 Besides PAH smooth muscle cells, we found a significant increase in E2F2 on both mRNA and protein levels. We also analyzed the expression of the E2F2 gene on other vascular cell types—endothelial cells and fibroblasts—using publicly available transcriptomic data sets. We didn't detect any obvious changes in E2F2 expression in pH compared to non-diseased cells. Of course, these transcriptomic findings require further validation on the protein level to confirm E2F2 functional relevance in PH pathobiology.

 E2F2 is a well-known regulator of G1-to-S phase progression. What makes it an attractive target compared with other cell-cycle regulators that have been explored in PAH?

The key [G1-to-S] regulators include cyclin D, CDK4 and 6, cyclin E, CDK2, RB, a family of E2F2 factors, and CDK inhibitors. It was well demonstrated that the CDK axis is indeed dysregulated in pH smooth muscle cells, and it has been directly studied in this context.

All current approaches either cause significant toxicity or fail to show clinical benefits in reversing the established vascular remodeling that drives pH progression. Unlike broad CDK inhibitors, E2F2 sits downstream in the pathway, potentially allowing more precise targeting of an abnormal vascular cell proliferation with fewer systemic side effects.

E2F2 may be more selectively [active] in PH smooth muscle cells, meaning targeting it could [better suppress] proliferative [programming], driving vascular remodeling more specifically than current approaches. Since E2F2 is an unexplored target in pH, it also offers a novel therapeutic angle that previously has not been addressed.

 You also showed that E2F2 knockdown reduced PASMC proliferation. How do you interpret the strength of that functional signal in terms of therapeutic potential?

We are at the early stage of discovery and in vitro stages of our studies. It's important to be both encouraged and appropriately cautious about functional effects. A strong anti-proliferative effect, which we detected in a cell-based system, tells us that we have genuine biological activity, that the target is engaged, and the pathway is responsive.

We interpret this data more as a proof-of-concept rather than a direct predictor of therapeutic outcomes, and the key questions we want to answer next [include]: Does this effect hold across multiple cell lines, and is the specific targeting of E2F2 physiologically achievable? How does it behave under more complex or stress conditions?

Overall, [the] positive in vitro [functional] effect, which we observed at this stage, supports its potential attractiveness as a target. Therapeutic potential ultimately depends on multiple other factors, which need to be further investigated.

 HIPK2 appears to regulate E2F2, but your data suggest this is independent of AKT and YAP signaling. Why is that independence important biologically or therapeutically?

YAP and AKT are well-established drivers of smooth muscle cell proliferation, apoptosis resistance in PH, and progressive vascular remodeling. However, [completely] inhibiting either target presents therapeutic challenges.

AKT plays essential roles in glucose homeostasis and cardiac survival signaling, [and its inhibition can lead to] toxicities, including hyperglycemia, cardiac dysfunction, and QT prolongation. YAP is equally indispensable [and] critical for normal tissue homeostasis, organ repair, and regeneration.

A more rational strategy is to simultaneously partially inhibit multiple independent pathways at subtherapeutic doses. In this approach, the synergetic efficacy is achieved without the toxicity of complete single-target blockade. It offers a mechanistically distinct node that could be incorporated into such a combination strategy and potentially improves therapeutic efficacy while maintaining an acceptable safety profile for pH patients.

 From a translational perspective, what are the biggest challenges in moving a target like E2F2 from mechanistic biology into a druggable pathway in PAH?

Transcriptional factors have historically been considered undruggable targets. However, recent advances offer genuine hope. Direct TF transcription factors inhibition has now been validated clinically, at least for heath 2f alpha and STAT3 inhibitor, which is entering phase 1 clinical trials. This demonstrates that transcription factors can be selectively targeted and provide a roadmap for targeting E2F2.

The second challenge is that E2F2 belongs to a functional and structurally related subgroup [that includes E2F1 and E2F3]. They share similar domain structures, overlapping target genes, and RB-dependent regulation. [The] loss of all 3 together leads to profound cell cycle arrest. This raises the concern that selective E2F2 inhibition may have limited therapeutic impact if E2F1 and if E2F3 can functionally substitute [for] each other and E2F2.

 Do you think E2F2 is more likely to serve as a direct therapeutic target, or as a biomarker of proliferative disease activity in pulmonary vascular remodeling?

It has [the] potential to be considered a therapeutic target. Using it as a biomarker is more challenging since it is a transcription factor [with] nuclear localization. No data indicate that it can be excreted and measured as a circulating biomarker.

However, we can't exclude the possibility that E2F2-related noncoding RNAs or mRNAs could potentially be detected in circulating extracellular vesicles or exosomes. This, of course, required further investigation.

 What is the next critical step to validate this pathway in vivo or in human disease before it could influence PAH treatment strategies?

We're also planning to evaluate the in vitro effects of E2F2 downregulation in non-diseased PA smooth muscle cells since we're hoping that downregulation of E2F2 [will] have detrimental effects only in diseased cells. By this, we hope to reduce systemic toxicity, minimize the potential of target effects and other cell types, and overall improve the safety profile of this new novel therapeutic strategy.

) E2F Transcription Factor 2 (E2F2) Supports Increased Proliferation in Pulmonary Arterial Smooth Muscle Cells in Pulmonary Arterial Hypertension. Late breaker presented at ATS 2026 in Orlando, Florida, on May 20.


In this Q&A, Tatiana V. Kudryashova, PhD, discusses new data presented at ATS 2026 that show silencing E2F2 suppresses hyperproliferation in PAH smooth muscle cells.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Could E2F2 Offer a More Precise Anti-Remodeling Target in PAH?

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Pooled B-Well phase 3 data show bepirovirsen achieved a 19% functional cure rate in CHB vs 0% with standard of care alone.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The FDA has approved fast-acting inhaled insulin Afrezza for pediatric patients aged 6-18 years with T1D or T2D.

Type 1 Diabetes

Type 2 Diabetes

FDA News

This episode covers the FDA’s recent approval of MannKind’s inhaled insulin Afrezza for patients aged 6-18 years with either T1D or T2D.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue: FDA Approves Afrezza Inhaled Insulin for Pediatric Patients

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recent approval of the Libre Duo and Libre Duo 10 Day monitors.

The World’s First Dual Glucose-Ketone Monitor Receives Clearance in Europe

This segment of the May episode of The Medical Sisterhood highlights the importance of addressing patients' and parents' fears in dermatology.

Addressing Pediatric Patients' and Caregivers' Fears in Dermatology, With Lisa Swanson, MD

Compare statins, ezetimibe, bempedoic acid and PCSK9 inhibitors for side effects, dosing preferences, and shared decision-making tips.

Adherence, Persistence, and Long-Term Success in ASCVD Lipid-Lowering Therapy

Compare statin side effects with ezetimibe, bempedoic acid and PCSK9 inhibitors, plus practical dosing tips and shared decision-making.

Safety, Tolerability, and Patient-Centered Decision-Making in ASCVD Lipid Therapy

Christopher G. Bunick, MD, PhD, is an associate professor of dermatology at Yale University School of Medicine.

Amlitelimab was discussed in the ABCs in Dermatology podcast, with the hosts highlighting atopic dermatitis patient demographics and high disease burden.

What Does New Phase 3 Amlitelimab Data Suggest for Atopic Dermatitis?

Heather Johnson, MD, is a preventive cardiologist at Lynn Women’s Health and Wellness Institute in Baptist Health South Florida and a clinical affiliate associate professor at Florida Atlantic University.

Heather Johnson, MD, discusses progress in providing more individualized care to female cardiovascular patients, as well as what remains to be done.

Recent Advancements and Ongoing Roadblocks in Cardiovascular Care for Women

Igor Barjaktarevic, MD, PhD, is the medical director of the chronic obstructive pulmonary disease program at the David Geffen School of Medicine at UCLA.

Igor Barjaktarevic, MD, discussed findings at ATS 2026, where the recombinant therapy outperformed weekly plasma-derived augmentation on key pharmacokinetic endpoints.

Latest News

The HCPFive: Top News for Healthcare Providers from the Week of 05/24

Retatrutide Provides Substantial Weight Loss in Patients With Obesity or Overweight

Endotyping & Biomarkers in CSU, With Jonathan Bernstein, MD

Discussing Zumilokibart Data in Atopic Dermatitis, With Ruth Ann Vleugels, MD, MPH, MBA

Could E2F2 Offer a More Precise Anti-Remodeling Target in PAH?